Tokyo, Japan – Nov. 29, 2006 – REGiMMUNE Corporation announced today the appointment of Mr. Hiroki NARITA, the Deputy General Manager, Investment Group, NIF SMBC Ventures, Japan, to its Board of Directors.
Mr. Narita has participated in the investment of approximately $40 million in 11 biotechnology companies, including MediciNova, Inc. and LTT Bio-Pharma Co., Ltd. Mr. Narita currently serves on the Board of Directors of Cardio Incorporated and Ribomic Inc.
“I’m pleased to welcome Mr. Narita as a new member of the REGiMMUNE Board. He is recognized nationally for his experience as a venture capitalist in the biotech industry. We believe that the addition of Mr. Narita will help us maintain an adequate balance of governance by our shareholders and also will lead the board to make discerning decisions,” commented Mr. Haru MORITA, President and Chief Executive Officer.
REGiMMUNE (www.regimmune.com) is a biotechnology company focused on the immune regulating system for product development using a patented platform technology that can activate the immune regulation system. The technology has been successfully applied to reVax technology, which bore REGiMMUNE’s own pipelines. The company is currently focusing its platform on the development and manufacturing of therapeutic compounds for the treatment of allergies and autoimmune disease.
For Information Contact:
Yuko Amizaki, Director, Corporate Planning
REGiMMUNE.
+81-3-3456-0820